Autoimmune diseases represent a heterogeneous group of disorders in which the immune system erroneously targets self-antigens, leading to chronic inflammation, tissue destruction, and organ dysfunction. Conditions such as rheumatoid arthritis (RA), multiple sclerosis (MS), type 1 diabetes (T1D), systemic lupus erythematosus (SLE), and inflammatory bowel disease (IBD) affect millions worldwide and impose a substantial burden on patients and healthcare systems. Current therapeutic strategies largely rely on systemic immunosuppression using corticosteroids, disease-modifying antirheumatic drugs (DMARDs), or biologic agents that broadly dampen immune activity. While these treatments can control symptoms and slow disease progression, they are often accompanied by significant side effects, including increased susceptibility to infections, organ toxicity, and lack of selectivity for pathogenic immune cells. The need for more precise, safer, and more effective therapeutic modalities has driven intense research into nanotechnology-based drug delivery systems. Nanocarriers—engineered particles with dimensions typically below 200 nanometers—offer a transformative platform for delivering autoimmune therapies directly to the sites of inflammation or to specific immune cell subsets. This article explores innovative approaches using nanocarriers for autoimmune therapy, detailing the underlying mechanisms, the types of carriers under investigation, current preclinical and clinical advances, and the challenges that remain.

What Are Nanocarriers?

Nanocarriers are colloidal drug delivery vehicles engineered from a variety of materials, including lipids, polymers, inorganic compounds, and hybrid composites. Their nanoscale size imparts unique physical and chemical properties, such as a high surface-area-to-volume ratio, tunable surface chemistry, and the ability to cross biological barriers like the endothelial lining of blood vessels and the blood-brain barrier. Nanocarriers can encapsulate a wide range of therapeutic agents—small-molecule drugs, peptides, proteins, nucleic acids (siRNA, mRNA, DNA), and even imaging agents—protecting them from degradation and improving their pharmacokinetic profiles.

Surface functionalization is a key design element. By attaching targeting ligands (e.g., antibodies, peptides, aptamers, or folate), nanocarriers can bind specifically to receptors overexpressed on activated immune cells or inflamed tissues. This active targeting enhances drug accumulation at the intended site while reducing systemic exposure. Additionally, nanocarriers can be engineered to respond to environmental stimuli—such as pH, redox potential, enzyme activity, or temperature—enabling triggered drug release at the pathological focus. These capabilities make nanocarriers exceptionally well-suited for treating autoimmune diseases, where spatial and temporal control of immunomodulation is critical.

Innovative Approaches in Autoimmune Therapy

Nanocarrier-based strategies for autoimmune diseases are evolving rapidly, moving beyond simple encapsulation toward sophisticated systems that orchestrate immune responses with high precision. Some of the most promising innovative approaches are detailed below.

Targeted Delivery to Pathogenic Immune Cells

A hallmark of autoimmunity is the activation of self-reactive T cells and B cells that drive tissue damage. Nanocarriers can be designed to home in on these cells by displaying ligands for surface markers uniquely expressed during autoreactivity. For example, in RA, synovial fibroblasts and infiltrating T cells upregulate folate receptor beta (FR-β). Folate-decorated liposomes loaded with methotrexate have demonstrated enhanced accumulation in arthritic joints and improved therapeutic efficacy in murine models. Similarly, targeting CD4+ T cells with anti-CD4 antibody-conjugated nanoparticles has been explored to deliver immunosuppressive agents like rapamycin, inducing tolerance without global immune suppression. Researchers are also employing peptide-major histocompatibility complex (pMHC) coated nanoparticles to engage autoreactive T cell receptors, steering them toward anergy or deletion. These approaches represent a paradigm shift from blanket immunosuppression to selective immunomodulation.

Controlled and Stimuli-Responsive Release

Nanocarriers enable sustained, controlled release of therapeutics, which can maintain therapeutic drug levels over extended periods, reduce dosing frequency, and minimize peak-related toxicity. Polymeric nanoparticles made from poly(lactic-co-glycolic acid) (PLGA) or chitosan can degrade slowly over weeks, releasing encapsulated cytokines, steroids, or small molecules in a predictable manner. More advanced systems incorporate stimuli-responsive elements. For instance, pH-sensitive nanocarriers exploit the acidic microenvironment of inflamed tissues; at lower pH (~6.5-7.0), the carrier disassembles or becomes permeable, releasing its payload preferentially at the disease site. Enzymatic triggers—such as matrix metalloproteinases (MMPs) upregulated in arthritic joints—can also be harnessed. Hydrogel-based nanoparticles crosslinked by MMP-cleavable peptides release their cargo only in the presence of these enzymes, providing spatiotemporal control. Oxidation-responsive nanocarriers that degrade under the high reactive oxygen species (ROS) levels found in autoimmune lesions are another active area of research.

Co-Delivery of Multiple Agents

Autoimmune diseases often involve multiple pathological pathways. Nanocarriers can simultaneously deliver combinations of drugs, such as an anti-inflammatory agent and a tolerogenic signal, to achieve synergistic effects. For example, lipid nanoparticles co-encapsulating dexamethasone and transforming growth factor beta (TGF-β) have been shown to promote regulatory T cell (Treg) expansion while suppressing effector T cells in murine colitis models. Similarly, nanoparticles delivering both a self-antigen and an immunomodulatory molecule (e.g., rapamycin) have been used to induce antigen-specific tolerance, a strategy now being investigated for prevention of T1D and treatment of MS. The ability to load multiple cargos with distinct release kinetics within a single nanocarrier opens new avenues for combination immunotherapy.

Cell Membrane-Coated Nanocarriers

A particularly innovative approach involves cloaking synthetic nanoparticles in cell membranes derived from immune cells, red blood cells, or platelets. This biomimetic coating endows the nanocarriers with natural surface proteins that allow them to evade immune clearance, target inflamed endothelium, or even bind to autoreactive antibodies. For instance, macrophage membrane-coated nanoparticles can sequester pro-inflammatory cytokines like tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6), functioning as decoys that neutralize these mediators while avoiding the side effects of systemic blockade. Neutrophil membrane-coated nanocarriers have been shown to suppress arthritis by targeting inflamed synovium and delivering anti-inflammatory agents. This platform combines the engineering versatility of synthetic particles with the complex functionality of natural cells.

Types of Nanocarriers Used in Autoimmune Therapy

A diverse arsenal of nanocarrier platforms is under investigation, each offering distinct advantages for autoimmune applications. Below is an expanded overview of the most widely studied classes.

Liposomes

Liposomes are spherical vesicles composed of one or more phospholipid bilayers enclosing an aqueous core. They are biocompatible, can encapsulate both hydrophilic (in the core) and lipophilic (in the bilayer) drugs, and have been extensively studied for drug delivery. Surface modification with polyethylene glycol (PEG) creates "stealth" liposomes that avoid rapid clearance by the mononuclear phagocyte system, prolonging circulation times. Ligand-targeted liposomes, such as those decorated with anti-CD20 antibodies (rituximab-conjugated), have been evaluated in murine lupus models to deplete B cells while reducing systemic toxicity. Liposomal corticosteroids (e.g., prednisolone phosphate liposomes) have shown improved therapeutic indices in RA and MS models. Several liposomal formulations for autoimmune diseases have reached clinical trials, though none have yet received regulatory approval for this indication.

Polymeric Nanoparticles

Polymeric nanoparticles are solid particles made from natural or synthetic polymers. PLGA, polycaprolactone (PCL), chitosan, and hyaluronic acid are common choices. They offer excellent stability, high drug loading, and tunable degradation rates. PLGA nanoparticles loaded with rapamycin have been used to induce immune tolerance in models of T1D and MS. Polymeric micelles—amphiphilic block copolymer self-assemblies—provide a versatile platform for delivering hydrophobic immunomodulators. Moreover, cationic polymers like polyethyleneimine (PEI) are used to complex nucleic acids for gene therapy approaches, such as delivering siRNA to silence pro-inflammatory cytokines. The size, charge, and surface chemistry of polymeric nanoparticles can be precisely controlled, making them highly customizable.

Solid Lipid Nanoparticles (SLNs) and Nanostructured Lipid Carriers (NLCs)

SLNs are composed of solid lipids (e.g., triglycerides, waxes) stabilized by surfactants. They offer high drug loading for lipophilic compounds, controlled release, and low toxicity due to the use of physiological lipids. NLCs are a second generation that incorporate liquid lipids to increase drug loading and release flexibility. SLNs loaded with cyclosporine A have been investigated for topical treatment of chronic plaque psoriasis, showing enhanced skin penetration and reduced systemic absorption. SLNs containing tacrolimus have also been developed for atopic dermatitis. Their solid matrix can protect labile drugs and allow for sustained release over days.

Inorganic Nanoparticles

Inorganic nanoparticles—including gold, iron oxide, silica, and mesoporous silica—offer unique physical properties useful for imaging, thermal therapy, and drug delivery. Gold nanoparticles (AuNPs) can be functionalized with ligands and loaded with drugs; they also generate heat upon near-infrared irradiation, enabling photothermal ablation of pathogenic immune cells. Iron oxide nanoparticles are superparamagnetic, serving as contrast agents for MRI while also allowing magnetic targeting to inflamed sites. Silica nanoparticles have large surface areas for drug loading and can be engineered to release payloads in response to pH or enzymes. However, concerns about long-term toxicity and biodegradation of inorganic nanoparticles require careful evaluation before clinical translation.

Dendrimers and Carbon Nanomaterials

Dendrimers are branched, tree-like macromolecules with monodisperse sizes and many functional groups on their periphery. Polyamidoamine (PAMAM) dendrimers have been conjugated with methotrexate or anti-inflammatory peptides for targeted delivery. Carbon nanomaterials, including carbon nanotubes and graphene oxide, have been explored as carriers—though their use in autoimmune therapy is less advanced due to potential toxicity. Overall, liposomes and polymeric nanoparticles remain the most translationally advanced platforms.

Preclinical and Clinical Applications in Autoimmune Diseases

Nanocarrier-based therapies have demonstrated encouraging results across multiple autoimmune indications. Here we highlight selected examples from preclinical studies and clinical trials.

Rheumatoid Arthritis (RA)

Rheumatoid arthritis is characterized by chronic synovial inflammation, joint destruction, and systemic inflammation. Numerous nanocarrier systems have been tested in collagen-induced arthritis (CIA) mouse models. Folate-targeted liposomal methotrexate significantly reduced paw swelling and bone erosion compared to free methotrexate. PEGylated PLGA nanoparticles loaded with the corticosteroid betamethasone produced prolonged anti-inflammatory effects and reduced joint damage. In a Phase I trial, arthritic patients received intravenous liposomal prednisolone phosphate; the formulation was well-tolerated and showed signs of clinical improvement, though larger studies are needed. More recently, macrophage membrane-coated nanoparticles that neutralize TNF-α have been evaluated in preclinical RA models, showing superior efficacy in reducing inflammation compared to anti-TNF antibodies alone.

Multiple Sclerosis (MS)

In MS, demyelination and neurodegeneration result from autoimmune attack on myelin-producing oligodendrocytes. Experimental autoimmune encephalomyelitis (EAE) is the classic animal model. Polymeric nanoparticles containing myelin antigens coupled with rapamycin have been used to induce immune tolerance. In EAE mice, these "tolerogenic nanoparticles" prevented disease onset and reversed established paralysis by expanding myelin-specific Tregs and suppressing pathogenic Th17 responses. Another approach uses liposomal formulations of glatiramer acetate—a clinically approved MS drug—to enhance delivery across the blood-brain barrier and improve efficacy. A clinical trial using a liposomal formulation of corticosteroids for MS relapses (NCT03022370) completed Phase II, showing reduced brain lesions and improved patient outcomes.

Systemic Lupus Erythematosus (SLE)

SLE is a complex, multi-organ autoimmune disease driven by autoantibodies and immune complex deposition. Nanocarriers designed to deplete pathogenic B cells or modulate dendritic cells have been studied. In lupus-prone mice, anti-CD20 immunoliposomes loaded with doxorubicin reduced splenic B cell numbers and autoantibody levels without bone marrow toxicity. PLGA nanoparticles delivering a peptide derived from the lupus autoantigen SmD have been tested to restore immune tolerance, showing decreased proteinuria and improved survival. Clinical translation for SLE remains early, but a Phase I trial of a liposomal glucocorticoid formulation in lupus nephritis is ongoing (NCT02595636).

Type 1 Diabetes (T1D)

Type 1 diabetes results from autoimmune destruction of pancreatic beta cells. Nanocarrier-based strategies aim to halt beta cell destruction or regenerate insulin-producing cells. In non-obese diabetic (NOD) mice, PLGA nanoparticles co-loaded with insulin peptide B:9-23 and the immunosuppressant rapamycin induced antigen-specific tolerance, delaying diabetes onset. Liposomes carrying beta cell antigens and immune-modulating molecules are also being explored. Additionally, nanoparticles delivering microRNA-146a (a negative regulator of inflammation) have shown promise in preserving beta cell function. A clinical trial using a tolerogenic nanoparticle approach for recent-onset T1D is currently in the planning stages.

Inflammatory Bowel Disease (IBD)

IBD, including Crohn's disease and ulcerative colitis, involves chronic intestinal inflammation. Orally administered nanocarriers can target inflamed intestinal mucosa directly. Chitosan nanoparticles loaded with budesonide have shown enhanced adhesion to inflamed tissue, providing local anti-inflammatory effects with minimal systemic exposure. Silica nanoparticles carrying anti-TNF antibodies have been developed for oral delivery. Another innovative approach uses hyaluronic acid-based nanoparticles targeting CD44 receptors overexpressed on activated macrophages in the colon, effectively delivering rapamycin in mouse colitis models.

Challenges and Future Directions

Despite the enormous potential of nanocarriers in autoimmune therapy, several hurdles must be overcome to translate these innovations into routine clinical practice.

Toxicity and Biocompatibility

Nanoparticles can induce unintended effects, such as oxidative stress, inflammatory responses, or accumulation in off-target organs (liver, spleen, kidneys). The long-term fate of non-biodegradable inorganic particles is a particular concern. Comprehensive toxicological evaluation is required. Surface modifications with PEG or biomimetic coatings can reduce immunogenicity, but may also elicit anti-PEG antibodies over time, limiting repeated dosing.

Immune Recognition and Clearance

Even stealth nanocarriers can be opsonized and cleared by the mononuclear phagocyte system, reducing their targeting efficiency. Developing "cloaking" technologies—such as coating with CD47 peptide to inhibit phagocytosis—is an active area of research. Additionally, the enhanced permeability and retention (EPR) effect, which facilitates nanoparticle accumulation in solid tumors, is less prominent in many autoimmune lesions, necessitating active targeting strategies.

Manufacturing Scalability and Quality Control

Producing nanocarriers at clinical scale with consistent size, drug loading, and release profiles is technically challenging. Batch-to-batch variability must be minimized. Sterilization methods (e.g., filtration, radiation) may affect nanoparticle properties. Regulatory pathways for nanomedicines are still evolving, and clear guidelines for characterization and quality control are needed. The US FDA and EMA have issued draft guidance documents, but industry-wide standards remain incomplete.

Targeting Specificity and Heterogeneity

Autoimmune diseases are heterogeneous, with patient-specific antigens and immune profiles. A "one-size-fits-all" nanocarrier may not work. Future personalized nanomedicines could incorporate patient-specific biomarkers, such as autoantibody profiles, to design custom targeting ligands. Advances in high-throughput screening and machine learning may accelerate the identification of optimal nanoparticle designs for individual patients.

Combination Therapies and Synergy

Nanocarriers that deliver multiple agents—such as an antigen plus a tolerogenic signal—are showing great promise for inducing durable immune tolerance. Future systems may combine checkpoint inhibitors, cytokine modulators, and cell surface modifiers in a single carrier. Integrating therapeutic efficacy with diagnostic capabilities (theranostics) is another frontier: nanoparticles that enable real-time imaging of drug distribution and disease response could guide treatment decisions.

Conclusion

Nanocarrier technology represents a paradigm shift in the management of autoimmune diseases, offering unprecedented opportunities for targeted, controlled, and personalized therapy. By enabling precise delivery of immunomodulatory agents to pathogenic cells and tissues, nanocarriers can enhance efficacy while minimizing the toxicity associated with systemic immunosuppression. From liposomes and polymeric nanoparticles to biomimetic membrane-coated systems and stimuli-responsive carriers, the diversity of platforms under development is matched only by the diversity of autoimmune conditions they aim to treat. Despite persistent challenges in toxicity, manufacturing, and regulatory approval, the field is moving rapidly toward clinical translation. As our understanding of autoimmune pathogenesis deepens and nanofabrication techniques mature, nanocarrier-based therapeutics hold the potential to alter the course of diseases that have long defied effective management. Continued investment in interdisciplinary research and collaboration between nanotechnologists, immunologists, and clinicians will be essential to realize this promise.